Advanced Clinical announces their adoption and incorporation of a risk-based monitoring approach to their clinical studies through the selection of TRI’s OPRA RBM technology platform and their accompanying RBM service offerings.
Following a six month long industry wide technology assessment, Advanced Clinical, (Advanced) has selected Triumph Research intelligence (TRI) as their RBM technology and services partner. TRI will be providing the OPRA platform for all of Advanced’s studies whose sponsors have requested a risk-based approach to monitoring with the objective of improving operational efficiency, quality, and patient safety. Conjointly, TRI will be supporting Advanced in optimizing their monitoring processes, implementing change management, and supporting study specific key risk indicator design.
Advanced Clinical is a Chicago-based, full service global CRO. Advanced provides CRO, patient recruitment, FSP, strategic staffing, and consulting services to a range of sponsors, with global representation in over 50 countries. Advanced is a forward-looking CRO that understands how the implementation and adoption of appropriate technologies will allow them to differentiate operationally, as well as offer greater levels of efficiency and quality to their sponsors. Advanced has involved key sponsors in the vendor selection process and will start the RBM journey with a fully engaged partnership of sponsor, CRO, and vendor.
Triumph Research Intelligence is a Raleigh-based clinical technology company, founded in 2013 as the technology arm of the long established industry consultancy, Triumph Consultancy Services. TRI is the first and currently the only company exclusively focused on quality oversight and risk-based monitoring, having developed the OPRA RBM technology platform specifically for trial quality oversight and risk-based monitoring. In addition to providing the first purpose built RBM technology, TRI leverages Triumph’s 14 years of industry consulting experience to provide a complete range of RBM specific professional services to ensure their customers not only have the best technology for RBM, but the processes and capabilities needed to truly benefit from that technology.
“We are excited to have chosen TRI as our technology and services partner. Their OPRA technology is well designed and has been enhanced through an intensive 18 month period of industry piloting and consultation with industry bodies and regulatory agencies. This, coupled with their comprehensive understanding of the RBM space and trial operations in general, gives us the confidence that together Advanced Clinical and TRI will provide the best possible overall RBM service solution,” said Julie Ross, EVP Advanced Clinical. “We didn’t take the decision lightly, and evaluated more than ten different vendors before selecting TRI as our full service RBM provider. It was important to us that we found a company who we could really partner with through this period of development and growth for our business and the industry as a whole, as well as a solution that would meet our customer’s RBM needs. Adopting OPRA is going to allow us to enhance the levels of oversight and insight to the trials we conduct which translates to a better clinical experience for our sponsors and the patients taking part in the trials we manage.”
“We are thrilled to have been selected as Advanced’s RBM technology provider and implementation partner. We are thoroughly impressed with Advanced’s vision for their company and the open and honest approach they have taken throughout the vendor selection process,” said Duncan Hall, CEO of TRI. "The design of the first RBM studies are already underway, and the Advanced operations team is great to work with. With their willingness to develop their capabilities through this period of incredible change in the industry, Advanced is demonstrating their forward thinking approach to this positive change, not only formulating but implementing such strategies for future success. We look forward to supporting them as a partner throughout the RBM journey while continuing to explore the possibilities of predictive analytics and big data in the clinical trials industry.”
Additional Information About Advanced Clinical Advanced Clinical is a full-service, global, clinical development organization built to deliver a truly better clinical trial experience for our clients. For over 20 years, Advanced has been providing full-service CRO, FSP, and strategic staffing solutions for Pharmaceutical, Biopharmaceutical, Biotechnology, and Medical Device organizations. To learn more, visit http://www.advancedclinical.com.
About Triumph Research Intelligence
Built on the foundation of Triumph’s 14 years of consulting exclusive to the clinical trials industry, TRI was established in 2013 in order to address the growing regulatory need for the industry to be able to provide evidence of quality oversight and decision making traceability during clinical trial execution. TRI’s OPRA platform has been designed from the ground up, specifically for this purpose and provides an accessible, affordable, hosted and fully 21CFR part 11 compliant environment for quality oversight and risk-based monitoring. Understanding that quality oversight and RBM is not just about technology, TRI provides a full suite of RBM specific services for companies wishing to start or improve on their RBM capabilities. These services include risk assessment, training, KRI design, change management and technology implementation.
Our mission is to improve trial efficiency, quality and patient safety through the practical application of our technology and professional services.
For more information, visit www.tritrials.com
Merck Launches Phase III Trials of Once-Monthly Oral HIV PrEP Candidate MK-8527
July 14th 2025In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in sub-Saharan Africa.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.
New FDA Initiative Reveals Common Reasons for Drug Application Rejection
July 11th 2025By publishing more than 200 complete response letters, the FDA is offering new visibility into the issues that most often delay drug approvals, including safety concerns, trial design flaws, and manufacturing gaps.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.